Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Story3
Bubble Holdings files Schedule 13D on Zevia PBC stake tied to October securities purchase deal
Bubble Holdings, LLC, GP Investments, Ltd. and GP Cash Management, Ltd. filed a Schedule 13D on 29 October 2026 disclosing a stake in Zevia PBC linked to a Securities Purchase Agreement and Registration Rights Agreement dated 22 October 2026.
HoldCo Asset Management discloses stake in BankUnited via Schedule 13D
A Schedule 13D filed with the SEC on 28 October 2026 shows HoldCo Asset Management, LP and affiliated entities reporting a holding in BankUnited, Inc. as of 21 October 2026.
OrbiMed-affiliated fund OPI VII reports 12.3% stake in Aspen Neuroscience
A Schedule 13D filed on 6 November 2026 shows OPI VII, a Delaware limited partnership managed by OrbiMed Advisors LLC, holds 3,589,132 shares of Aspen Neuroscience, Inc., equal to approximately 12.3% of the company's outstanding shares.
Company or person2
HE GP LLC
Company
AEROEQUITY GP, LLC
Company
Primary record20
Metropolitan Bank Holding Corp. filed SCHEDULE 13D/A
on Form 8-K filed on October 20, 2026. Y Patriot Financial Partners GP III, L.P. a AF N DE 0.00 584946.00 0.00 584946.00 584946.00 N 4.76 PN This calculation is based on 12,285,553 shares of Common Stock of the Issuer ou
Eton Pharmaceuticals, Inc. filed SCHEDULE 13G/A
, as amended, or otherwise. One Boston Place, 26th Floor, Boston, MA 02108 Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Delaware James Silverman - United States Y 2,440,000.00 Items 4(a) through 4(c) reflect t
Opaleye Management Inc. filed SCHEDULE 13G/A
, as amended, or otherwise. One Boston Place, 26th Floor, Boston, MA 02108 Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Delaware James Silverman - United States Y 1,120,000.00 3.76% Based on 29,769,466 shares
Gossamer Bio, Inc. filed SCHEDULE 13G/A
, as amended, or otherwise. One Boston Place, 26th Floor, Boston, MA 02108 Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Delaware James Silverman - United States Y 426,989.00 6.98 % 0 426,989.00 0 426,989.00 Y
Apollo Commercial Real Estate Finance, Inc. filed SCHEDULE 13G
0001193125-26-452127.txt : 20261106 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001929389 XXXXXXXX LIVE Common Stock, $0.01 par value 10/30/2026 0001467760 Apollo Commercial Real Estate Finance, Inc. 03762U105 c/o
FG Imperii Acquisition Corp. filed SCHEDULE 13G/A
on July 24, 2026. The Investment Manager serves as the investment manager to HB Strategies LLC, in whose name the securities reported herein are held. As such, the Investment Manager may be deemed to be the beneficial ow
Brilliant Earth Group, Inc. filed SCHEDULE 13G/A
0001193125-26-452170.txt : 20261106 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001883367 XXXXXXXX LIVE 3 Class A common stock, $0.0001 par value per share 09/30/2026 0001866757 Brilliant Earth Group, Inc. 109
GameSquare Holdings, Inc. filed SCHEDULE 13D/A
0001193125-26-451830.txt : 20261106 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001040463 XXXXXXXX LIVE 7 Common Stock, par value of $0.0001 10/26/2026 false 0001714562 36468G202 GameSquare Holdings, Inc. 6775
Opaleye Management Inc. filed SCHEDULE 13G/A
0001493152-26-050453.txt : 20261106 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001493152-26-035625 0001595855 XXXXXXXX LIVE 2 Common Stock, par value $0.0001 per share 09/30/2026 0001841330 Pasithea Therapeut
Saba Capital Management, L.P. filed SCHEDULE 13D/A
, the beneficial owner of the Common Shares reported herein. The address of the business office of each of the Reporting Persons is 405 Lexington Avenue, 58th Floor, New York, New York 10174. The principal business of: (
Ethos Technologies Inc. filed SCHEDULE 13G/A
on May 1, 2026, and subsequently amended on August 7, 2026. This Amendment is the final amendment to the Schedule 13G and constitutes an exit filing for the reporting persons. GV 2019 GP, L.P. DE 0.00 0.00 0.00 0.00 0.00
Bambusa Therapeutics, Inc. filed SCHEDULE 13D
, as amended, (the "Act") is filed as Exhibit 99.1. The Reporting Persons' ownership of the Issuer's securities includes (i) 5,933,787 shares of common stock held directly by the Fund; and (ii) 1,495,971 shares of common
Eos Energy Enterprises, Inc. filed SCHEDULE 13G
on August 5, 2026, and assumes the exercise of the warrants and the exchange of the Frontier Units held by Hudson Bay Master Fund Ltd., HT Investments MA LLC and HBC MSF Capital Solutions Blocker II LLC. The Investment M
CODEXIS, INC. filed SCHEDULE 13G/A
0001493152-26-050456.txt : 20261106 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001493152-26-021299 0001595855 XXXXXXXX LIVE 5 Common Stock, par value $0.0001 per share 09/30/2026 0001200375 Codexis, Inc. 1920
Opaleye Management Inc. filed SCHEDULE 13G/A
0001493152-26-050454.txt : 20261106 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001493152-26-021483 0001595855 XXXXXXXX LIVE 5 Ordinary Shares, par value NIS 1.00 per share. 09/30/2026 0001684693 Sol-Gel Techn
RA CAPITAL MANAGEMENT, L.P. filed SCHEDULE 13D/A
(the "SEC") on February 9, 2018, and amended on July 30, 2019, December 16, 2020, March 23, 2021, September 6, 2022, October 4, 2022, December 5, 2022, January 11, 2024, June 12, 2024, February 21, 2025, August 14, 2025,
HARROW, INC. filed SCHEDULE 13G/A
, as amended, or otherwise. One Boston Place, 26th Floor, Boston, MA 02108 Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Delaware James Silverman - United States Y 2,105,000.00 5.62 % 0 2,105,000.00 0 2,105,000
Guerrilla RF, Inc. filed SCHEDULE 13D/A
0001437749-26-035657.txt : 20261106 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001832887 XXXXXXXX LIVE 2 Common Stock, $0.0001 par value 11/04/2026 false 0001832487 40162G203 Guerrilla RF, Inc. 2000 PISGAH CH
Blackstone Holdings II L.P. filed SCHEDULE 13G
, as amended (the "Act"), or for any other purpose and each of the Reporting Persons expressly disclaims beneficial ownership of such shares of Class A Common Stock. The filing of this statement should not be construed t
Vir Biotechnology, Inc. filed SCHEDULE 13D/A
; or (j) Any action similar to any of those enumerated above. Items 5(a)-(c) of the Original 13D are hereby amended and supplemented as follows: AVF IX is the record owner of 5,055,689 shares of Common Stock ("AVF IX Rec